Melpispal 50 50 mg Powder and solvent for solution for injection
PDF Leaflet Revision Date: 18 April 2023
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of multiple myeloma and ovarian cancer.
Dosage (summary)
IV doses vary; 0.4 mg/kg (16 mg/mu00b2) every 4 weeks for myeloma; 1 mg/kg (40 mg/mu00b2) every 4 weeks for ovarian cancer.
Special Populations
- Elderly
- Renal impairment
- Paediatric population
Pregnancy & Breastfeeding
Contraindicated in pregnancy and breastfeeding.
Key Drug Interactions
- Live organism vaccines
- Nalidixic acid
- Busulfan
- Ciclosporin
Contraindications
- Hypersensitivity to melphalan
- Pregnancy and lactation
- Immunisation with live vaccines
Common side effects
- Bone marrow depression
- Leucopaenia
- Thrombocytopaenia
- Nausea
- Vomiting
Counselling Points
- Avoid live vaccines during treatment.
- Discuss fertility preservation options.
- Monitor for signs of infection and bleeding.
Serious warnings
- Myelosuppressive effects
- Risk of secondary malignancies
- Use only under experienced medical supervision
Important Disclaimer
The Melpispal 50 50 mg Powder and solvent for solution for injection professional information leaflet below is the property of Ruby Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
